 Cincinnati, Ohio -- Biotechnology company Aerpio Therapeutics has garnered $27 million in its first round of institutional venture capital investment.
Aerpio is developing small molecules and monoclonal antibodies to treat vascular disease and enhance wound healing.
Investors were led by the Novartis BioVenture Fund.
The company said proceeds will support ongoing development of its candidate pipeline. |